000			02011 a2200577 4500
005			20250515031906.0
264		0	_c20060818
008			200608s 0 0 eng d
022			_a1744-7658
024	7		_a10.1517/13543784.15.7.805 _2doi
040			_aNLM _beng _cNLM
100	1		_aGalili, Naomi
245	0	0	_aImmunomodulatory drugs in myelodysplastic syndromes. _h[electronic resource]
260			_bExpert opinion on investigational drugs _cJul 2006
300			_a805-13 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenesis Inhibitors _xadverse effects
650	0	4	_aAnimals
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aBlood Transfusion
650	0	4	_aCell Lineage
650	0	4	_aCells, Cultured _xdrug effects
650	0	4	_aChromosome Deletion
650	0	4	_aChromosomes, Human, Pair 5 _xultrastructure
650	0	4	_aClinical Trials as Topic
650	0	4	_aCytokines _xphysiology
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aDrugs, Investigational _xtherapeutic use
650	0	4	_aErythrocyte Transfusion
650	0	4	_aErythropoiesis _xdrug effects
650	0	4	_aFemale
650	0	4	_aHematopoietic Stem Cells _xdrug effects
650	0	4	_aHumans
650	0	4	_aImmunologic Factors _xadverse effects
650	0	4	_aLenalidomide
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyelodysplastic Syndromes _xdrug therapy
650	0	4	_aNF-kappa B _xantagonists & inhibitors
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aPilot Projects
650	0	4	_aThalidomide _xadverse effects
650	0	4	_aThrombocytopenia _xchemically induced
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
700	1		_aRaza, Azra
773	0		_tExpert opinion on investigational drugs _gvol. 15 _gno. 7 _gp. 805-13
856	4	0	_uhttps://doi.org/10.1517/13543784.15.7.805 _zAvailable from publisher's website
999			_c16381201 _d16381201